For HCPs Only
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed drug updates.

Drug Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

FDA data

Drug Reference

Drug approvals, labels, and clinical context.

Access structured FDA label data, dosage references, NDC records, interactions, and prescribing context.

Clinical Coverage

Additional Drug Updates

Rare Disease

FDA Approves Marnetegragene Autotemcel for Severe LAD-I in Pediatrics

May 9|3 min read|By Editorial Team
Endocrinology

FDA Approves Orforglipron for Obesity: Oral GLP-1 Therapy with No Food Restrictions

May 9|3 min read|By Dr. Amit Desai
Endocrinology

FDA Approves Afrezza for Pediatric Use: First Needle-Free Insulin for Children with Diabetes

May 9|3 min read|By Dr. Amit Desai
Neurology

FDA Approves Donanemab for Alzheimer: Subcutaneous Dosing Options Available

May 9|3 min read|By Dr. Vikram Patel
Obstetrics Gynecology

FDA Issues Guidance for Improved Pregnancy Safety Data Collection: Implications for Drugs and Biologics

May 9|3 min read|By Editorial Team
Endocrinology

FDA Approves Langlara and Ponlimsi: New Biosimilars for Insulin Access

May 9|3 min read|By Dr. Amit Desai
Endocrinology

FDA Proposes Exclusion of Semaglutide and Tirzepatide from 503B Bulks List: Impact on Compounding Access

May 9|3 min read|By Dr. Amit Desai
Endocrinology

GLP-1 Therapies: New WHO Guidelines for Obesity Management

May 9|3 min read|By Dr. Amit Desai
Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: New Subcutaneous Formulation Enhances Patient Access

May 9|3 min read|By Dr. Aditi Kulkarni
Otolaryngology

FDA Approves Lunsotogene Parvec for Genetic Hearing Loss: A New Era for OTOF Mutation Patients

May 9|3 min read|By Editorial Team
Endocrinology

FDA Approves Oral Semaglutide: New Dosing Guidelines for Obesity Management

May 9|3 min read|By Dr. Amit Desai
Neurology

FDA Approves Lecanemab for Alzheimer: Biweekly IV vs Weekly SC Dosing

May 9|3 min read|By Dr. Vikram Patel
Endocrinology

Insulin Icodec Reduces Dosing Frequency: Weekly vs Daily Basal Insulin in Type 2 Diabetes

May 9|3 min read|By Dr. Amit Desai
Neurology

FDA Approves Lecanemab for Alzheimer: Weekly Dosing Option Now Available

May 8|2 min read|By Dr. Aditi Kulkarni
Endocrinology

FDA Approves Insulin Icodec for Type 2 Diabetes: First Once-Weekly Basal Insulin

May 8|3 min read|By Dr. Amit Desai
Endocrinology

FDA Approves Orforglipron for Obesity: Oral GLP-1 Receptor Agonist with No Food Restrictions

May 8|3 min read|By Dr. Amit Desai
Pharmacology

FDA Updates Drug Approval Standard: One Trial Required for New Drugs

May 8|2 min read|By Editorial Team
Endocrinology

FDA Approves Insulin Glargine-Aldy Biosimilar for Diabetes: Interchangeable with Lantus

May 8|3 min read|By Dr. Amit Desai
Otolaryngology

FDA Approves Lunsotogene Parvec-Cwha for OTOF-Related Hearing Loss: First Gene Therapy for Deafness

May 8|3 min read|By Editorial Team
Dermatology

Dupilumab vs Tralokinumab vs Lebrikizumab vs Difamilast: Biologics Comparison for Atopic Dermatitis in 2025

May 7|3 min read|By Dr. Rohan Gupta
Rare Disease

FDA Approves Tividenofusp Alfa for Hunter Syndrome: First Neurologic Treatment in 20 Years

May 7|3 min read|By Editorial Team
Cardiology

Enlicitide Reduces LDL Cholesterol Significantly in Phase 3 Trial

May 7|3 min read|By Dr. Arjun Sharma
Oncology

FDA Approves Bispecific Antibodies for Oncology: New Mechanisms in Cancer Immunotherapy

May 7|3 min read|By Dr. Meera Pillai